Dengue subunit vaccine - Merck Sharp and Dohme

Drug Profile

Dengue subunit vaccine - Merck Sharp and Dohme

Alternative Names: DEN 1 80E; Dengue subunit vaccine - Hawaii Biotech; HB6; HBV-001 D1; Tetravalent dengue vaccine - Merck Sharp & Dohme; V 180

Latest Information Update: 21 Jan 2016

Price : $50

At a glance

  • Originator Hawaii Biotech
  • Developer Merck Sharp & Dohme; National Institute of Allergy and Infectious Diseases
  • Class Dengue vaccines; Subunit vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Dengue

Most Recent Events

  • 04 Dec 2015 Hawaii Biotech plans a phase I trial for Dengue in USA
  • 05 Nov 2015 Hawaii receives SBIR grant from NIH for Dengue vaccine development
  • 01 Apr 2015 Phase-I clinical trials in Dengue (In volunteers) in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top